Detalhe da pesquisa
1.
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.
Invest New Drugs
; 39(1): 142-151, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32556884
2.
Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
Clin Lung Cancer
; 24(8): 689-695.e1, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880074
3.
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
Cancer Treat Res Commun
; 36: 100743, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37531736
4.
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res
; 25(16): 4955-4965, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31142501
5.
Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
Oral Oncol
; 79: 9-14, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29598954
6.
Cancer in the elderly.
Trans Am Clin Climatol Assoc
; 117: 147-55; discussion 155-6, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-18528470
7.
Canalith repositioning for benign paroxysmal positional vertigo.
Otol Neurotol
; 26(4): 704-10, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16015173
8.
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck.
Head Neck
; 37(11): 1665-71, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24954745
9.
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Thyroid
; 19(3): 233-40, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19265494
10.
Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors.
Support Care Cancer
; 11(5): 313-20, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12720075